Evidence map›Paper›PMID 40034548›Full record

ArticleToxicology reports2025

Sergio Sifontes-Rodríguez, Juan Alberto Hernández-Aceves, Carlos Gerardo Salas-Garrido, Diego Moctezuma Rocha, Iván Nicolás Pérez-Osorio, Nelly Villalobos, Edda Sciutto, Gladis Fragoso

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sergio Sifontes-RodríguezDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.
Juan Alberto Hernández-AcevesDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.
Carlos Gerardo Salas-GarridoDepartamento de Patología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.
Diego Moctezuma RochaDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.
Iván Nicolás Pérez-OsorioDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.
Nelly VillalobosDepartamento de Patología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.
Edda SciuttoDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.
Gladis FragosoDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide drugs have emerged as an attractive alternative for cancer treatment due to their potency, high specificity, general safety and low cost. GK-1 is a linear 18 amino acid peptide with proven immunomodulator, antitumor and antimetastatic capacity in animal models. Preclinical toxicity studies for its use as a vaccine adjuvant demonstrated its safety in various assay systems, but a comprehensive exploration of its toxicity profile is required to be used in cancer immunotherapy. Therefore, in the present work, the potential toxicity of GK-1 was predicted with ToxinPred 3.0 software, and its

Indexed as

BALB/cCytotoxicityGK-1 peptideMouseRepeated-dose toxicitySingle-dose toxicityToxinPred 3.0

Identifiers

PMID40034548
PMCPMC11875144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.